CEFIXIME is a Oral Powder, For Suspension in the Human Prescription Drug category. It is labeled and distributed by Lupin Pharmaceuticals, Inc.. The primary component is Cefixime.
Product ID | 68180-405_88f79e17-9a30-4025-9fdc-d1311d78e895 |
NDC | 68180-405 |
Product Type | Human Prescription Drug |
Proprietary Name | CEFIXIME |
Generic Name | Cefixime |
Dosage Form | Powder, For Suspension |
Route of Administration | ORAL |
Marketing Start Date | 2015-04-24 |
Marketing Category | ANDA / ANDA |
Application Number | ANDA065129 |
Labeler Name | Lupin Pharmaceuticals, Inc. |
Substance Name | CEFIXIME |
Active Ingredient Strength | 100 mg/5mL |
Pharm Classes | Cephalosporin Antibacterial [EPC],Cephalosporins [CS] |
NDC Exclude Flag | N |
Listing Certified Through | 2022-12-31 |
Marketing Start Date | 2015-04-24 |
NDC Exclude Flag | N |
Sample Package? | N |
Marketing Category | ANDA |
Application Number | ANDA065129 |
Product Type | HUMAN PRESCRIPTION DRUG |
Billing Unit | ML |
Marketing Start Date | 2015-04-20 |
Inactivation Date | 2020-01-31 |
Ingredient | Strength |
---|---|
CEFIXIME | 100 mg/5mL |
SPL SET ID: | 6d68dbd9-7d75-4ff1-91db-79ff8ae879ec |
Manufacturer | |
UNII | |
RxNorm Concept Unique ID - RxCUI | |
UPC Code |
NDC | Brand Name | Generic Name |
---|---|---|
16714-766 | Cefixime | cefixime |
16714-767 | Cefixime | cefixime |
43598-673 | Cefixime | Cefixime |
43598-674 | Cefixime | Cefixime |
62250-663 | Cefixime | cefixime |
62250-664 | Cefixime | cefixime |
67877-584 | CEFIXIME | CEFIXIME |
68180-416 | CEFIXIME | CEFIXIME |
68180-405 | CEFIXIME | CEFIXIME |
68180-407 | CEFIXIME | CEFIXIME |
62250-668 | Cefixime | Cefixime |
65862-751 | Cefixime | Cefixime |
65862-752 | Cefixime | Cefixime |
68180-423 | CEFIXIME | CEFIXIME |
70518-2749 | CEFIXIME | CEFIXIME |
27437-201 | SUPRAX | cefixime |
27437-203 | SUPRAX | cefixime |
27437-205 | SUPRAX | cefixime |
27437-206 | SUPRAX | cefixime |
27437-207 | SUPRAX | cefixime |
27437-208 | SUPRAX | cefixime |
43063-537 | SUPRAX | cefixime |
54348-797 | SUPRAX | CEFIXIME |